Everence Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Everence Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,260	Closed	-$221K	–	763
2022 Q3	$221K	Hold	4,260	–	–	0.02%	615
2022 Q2	$201K	Hold	4,260	–	–	0.02%	649
2022 Q1	$303K	Hold	4,260	–	–	0.02%	557
2021 Q4	$319K	Buy	+4,260	New	+$334K	0.02%	568
2021 Q3	–	Sell	-4,780	Closed	-$210K	–	746
2021 Q2	$210K	Hold	4,780	–	–	0.02%	684
2021 Q1	$236K	Hold	4,780	–	–	0.02%	638
2020 Q4	$201K	Hold	4,780	–	–	0.02%	651
2020 Q3	$219K	Buy	+4,780	New	+$232K	0.02%	562
2019 Q3	–	Sell	-2,990	Closed	-$252K	–	653
2019 Q2	$252K	Hold	2,990	–	–	0.04%	474
2019 Q1	$286K	Buy	+2,990	New	+$268K	0.05%	427

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Everence Capital Management's ENTA Position: Q4 2022 in Review

Everence Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2022, closing a stake of 4,260 shares — an estimated $221K sold.

Everence Capital Management first reported a position in ENTA in Q1 2019 and held it in 10 quarters. The position peaked at $319K in Q4 2021. 146 funds tracked by Wall St. Rank hold ENTA as of Q4 2022.

Everence Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Everence Capital Management sold 4,260 Enanta Pharmaceuticals shares in Q4 2022, an estimated $221K.
Everence Capital Management first reported a position in Enanta Pharmaceuticals in Q1 2019 and held it in 10 quarters.
Everence Capital Management's Enanta Pharmaceuticals position peaked at $319K in Q4 2021.
146 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2022.

Based on Everence Capital Management's 13F filing for Q4 2022, filed 31 Jan 2023.